Atopic Dermatitis Market Size, Trends, Industry Analysis Report, By Drug Type; By Route of Administration; (oral, Injectable, Topical), By Therapy; (Photo Therapy, Directed Therapy), By End-Use; By Geography; Segment Forecast, 2024 - 2032
- Published Date:Jan-2024
- Pages: 117
- Format: PDF
- Report ID: PM1317
- Base Year: 2023
- Historical Data: 2019-2022
Report Outlook
The atopic dermatitis market was valued at USD 7.11 billion in 2023 and is expected to grow at a CAGR of 15.0% during the forecast period. The market for treating atopic dermatitis is anticipated to expand as the demand for this market is amplified by the introduction of cutting-edge medical technology and novel techniques; increased acceptability and speedy expansion of the revolutionary therapy in emerging nations are also anticipated to fuel the market's growth.
The Atopic Dermatitis Market report details key market dynamics to help industry players align their business strategies with current and future trends. It examines technological advances and breakthroughs in the industry and their impact on the market presence. Furthermore, a detailed regional analysis of the industry at the local, national, and global levels has been provided.
Know more about this report: Request for sample pages
The atopic dermis usually starts in childhood and can worsen as people mature. The inflammatory skin condition known as atopic dermatitis (AD) is a chronic or chronically relapsing condition brought on by changes in environment, immunologic, genetic, and pharmacological factors. According to a phenomenon known as the atopic march, allergic rhinitis and asthma are frequently co-occurring atopic disorders that first appear as atopic dermatitis (40–60% of the time). With lifetime incidence rates of 1-3% for adults and 15-20% for children globally, it is one of the most prevalent skin conditions.
According to the American Journal of Managed Care, up to 15 million Americans suffer from atopic dermatitis. Atopic dermatitis is common in infants; 10% to 20% of them will get it. However, about half of them outgrow it or significantly improve as they age. Both sexes are equally affected by atopic dermatitis, which is more prevalent in those with a personal or family history of asthma, environmental allergies, or food allergies. Anywhere on the skin might develop symptoms of atopic dermatitis. In youth and adults, it frequently affects the hands, inner elbows, neck, foot, knees, ankle, and the region around the eyes.
The patient is at a high risk since they have allergies that might cause morbidity, including allergies like asthma and allergic rhinitis. The illness has a potential for chronicity and can occasionally worsen and spread. To treat eczema and lessen irritation and other issues brought on by atopic dermatitis, atopic dermatitis medications, such as atopic eczema steroids, are employed.
Atopic dermatitis affects 67% of children who frequently experience sleep issues. A lack of sleep may hamper children's growth. In addition, they have asthma, allergic rhinitis, and food allergies. Atopic dermatitis typically begins in infancy and progresses into other allergy illnesses later in life. Those factors propel the atopic dermatitis market.
Know more about this report: Request for sample pages
Industry Dynamics
Growth Drivers
The market analysis for atopic dermatitis is driven by rising funding and government assistance for R&D. The development of novel techniques and the introduction of cutting-edge medical device technologies contribute to the expansion of the atopic dermatitis market value. The market's potential growth in the upcoming years may be enhanced by increasing knowledge of the disease's treatment alternatives.
The availability of appealing payment plans and government assistance in providing high-quality care at lower costs contribute to the industry's expansion. The infrastructure of hospitals and clinics may be upgraded with the newest technology to expand the global atopic dermatitis market. The market is expected to grow faster than average due to changes in climatic circumstances, an increase in the number of patients with various skin problems, and an increase in disposable income.
Governments from several industrialized and developing nations participate in campaigns to raise awareness about atopic dermatitis treatments. Similar to how new medications are being developed to treat atopic dermatitis, more clinical studies are being conducted, increasing demand for better atopic dermatitis therapies.
Atopic dermatitis market growth is also anticipated to be boosted by increased demand for novel biologics and product approvals. Additionally, it is expected that the increasing incidence of atopic dermatitis and the favourable reimbursement policies in emerging nations will propel market expansion.
Report Segmentation
The market is primarily segmented based on drug type, route of administration, therapy, end use, and region.
|
By Drug type |
By Route of administration |
By Therapy |
By End Use |
By Region |
|
|
|
|
|
Know more about this report: Request for sample pages
The injectable segment is acquired major market share over the forecast period
The injectable segment is dominated in 2022 and continue over the forecast period owing to the increased use of injectable medications such as Dupulimab. Also, other medicines will increase injectable use in the atopic dermatitis market. in addition, the lack of treatment for atopic dermatitis increased the chances for players to enter research and development and clinical trials for more medication will raise the injectable segment.
However, the oral segment is expected to increase at good pace over the period due to an increase in the use of oral medications.
The Hospitals segment dominated the market
The hospitals segment dominated the market in 2022 and continues the dominance over the forecast period owing to the high prevalence number of atopic dermatitis, the increase in prices of medication, and the increase in incomes of poor and middle-class families; also, government supports the funding for hospitals to improve their infrastructure are expected to expand the growth of hospitals segment.
The demand in North America is expected to witness significant growth.
The lucrative nature of this market in the North America is aided by the high frequency and increase in the number of patients suffering from various skin disorders, as well as the rise in disposable income, changes in the climate, better reimbursement policies, and growing business relationships between pharmaceutical companies and contract research organizations in emerging markets.
However, over the forecast, Asia Pacific is anticipated to have the fastest growth rates worldwide. It is due to the significant presence of quickly evolving healthcare technology, a sizable patient population, and increased spending.
Competitive Insight
Some of the major players operating in the global market include Galderma, Bristol-Myers Squibb Company, Novartis AG, Bausch Health, Bayer AG, Encore Dermatology, Inc., AstraZeneca, Teva Pharmaceutical Industries Ltd., Sanofi, Regeneron Pharmaceuticals, Mylan N.V., Boehringer Ingelheim International GmbH, GlaxoSmithKline plc.
Recent Developments
- In June 2022, Sanofi's Dupixent (dupilumab) was given the go-ahead by the US Food and Drug Administration (FDA) for treating children with moderate-to-severe atopic dermatitis aged six months to 5 years when topical prescription treatments are ineffective or inappropriate.
- In January 2022, The US FDA authorized Pfizer's CIBINQO (abrocitinib) for treating people with moderate to severe atopic dermatitis. Janus kinase 1 (JAK1) inhibitors are present in the oral medication CIBINQO (abrocitinib).
Atopic Dermatitis Market Report Scope
|
Report Attributes |
Details |
|
Market size value in 2024 |
USD 8.15 billion |
|
Revenue forecast in 2032 |
USD 25.00 billion |
|
CAGR |
15.0% from 2024 - 2032 |
|
Base year |
2023 |
|
Historical data |
2019 - 2022 |
|
Forecast period |
2024 - 2032 |
|
Quantitative units |
Revenue in USD billion and CAGR from 2024 to 2032 |
|
Segments Covered |
By Drug Type, By Route of Administration, By Therapy, By End User, By Region. |
|
Regional scope |
North America, Europe, Asia Pacific, Latin America; Middle East & Africa |
|
Key companies |
Galderma, Bristol-Myers Squibb Company, Novartis AG, Bausch Health, Bayer AG, Encore Dermatology, Inc., AstraZeneca, Teva Pharmaceutical Industries Ltd., Sanofi, Regeneron Pharmaceuticals, Mylan N.V., Boehringer Ingelheim International GmbH, GlaxoSmithKline plc. |
Want to check out the Atopic Dermatitis Market report before buying it? Then, our sample report has got you covered. It includes key market data points, ranging from trend analyses to industry estimates and forecasts. See for yourself by downloading the sample report.
Browse Our Top Selling Reports:
Veterinary Imaging Market Size, Share 2024 Report
Brain Monitoring Devices Market Size, Share 2024 Report
Medical Fiber Optics Market Size, Share 2024 Report
FAQ's
Key companies in atopic dermatitis market are Galderma, Bristol-Myers Squibb Company, Novartis AG, Bausch Health, Bayer AG, Encore Dermatology, Inc., AstraZeneca, Teva Pharmaceutical Industries Ltd., Sanofi, Regeneron Pharmaceuticals, Mylan N.V.
The atopic dermatitis market expected to grow at a CAGR of 15.0% during the forecast period.
The atopic dermatitis market report covering key segments are drug type, route of administration, therapy, end use, and region.
Key driving factors in atopic dermatitis market are increasing prevalence of atopic dermatitis drugs across the globe and availability of robust product portfolio.
The atopic dermatitis market size is expected to reach USD 25.00 billion by 2032.
